Publications by authors named "J Boursier"
Background & Aims: The accuracy of non-invasive tests (NITs) should be ≥80% (EASL recommendation). We aimed to compare the accuracies of the recommended NITs for advanced fibrosis in MASLD and improve NIT accuracy.
Methods: 1051 MASLD patients were allocated to derivation (n=637) and validation (n=414) sets.
Article Synopsis
- - Metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent among obese individuals and shows differences between sexes. A study sought to create a noninvasive blood test using mid-infrared (MIR) metabolic fingerprinting to diagnose metabolic dysfunction-associated steatohepatitis (MASH) in those with severe obesity.
- - The study involved 382 patients undergoing bariatric surgery, with liver biopsies assessed to establish a scoring algorithm based on MIR spectroscopy. In women, MASH was diagnosed in 14.3% of cases, showing high sensitivity (86%) and specificity (81%) for correctly identifying the condition.
- - For men, the test's performance was notably less effective, with a MASH diagnosis
Background: Patients with advanced chronic liver disease (ACLD) are at high risk of developing hepatocellular carcinoma (HCC). Therefore, biannual surveillance is recommended. This large-scale multicenter study aimed to stratify the risk of HCC development in ACLD.
View Article and Find Full Text PDFBackground & Aims: Despite its growing incidence, hepatocellular carcinoma (HCC) related to metabolic dysfunction-associated steatotic liver disease (MASLD) in non-cirrhotic livers remains poorly characterized. We compared the characteristics, management, survival, and trends of MASLD-related HCC in patients with or without underlying cirrhosis in a large multicenter cohort.
Methods: A total of 354 cases of MASLD-related HCC presented at the liver tumor meetings of four French university hospitals between 2007 and 2018 were included in the study.
Article Synopsis
- Scientists studied a health problem called MASH, which affects people's livers, and worked on two tests to help doctors tell if someone has it.
- They looked at data from over 3,000 people to make sure their first test, called acMASH, worked well, and then created a new test called acFibroMASH to find more severe cases.
- The new acFibroMASH test was better at predicting who might have future liver problems compared to another test, showing it's a useful tool for doctors to keep patients healthy.